J.P. Morgan and BofA Merrill Lynch were book-runners for the offering, with Leerink Partners, Canaccord Genuity and William Blair as co-managers, the company said..
The deal included 537,300 shares sold through an underwriters option to purchase additional shares, and resulted in aggregate proceeds of approximately $103 million, the Menlo Park, Calif.-based company said.
On opening the follow-on offering earlier this month, Intersect ENT said it planned to float 3 million shares, with an expected 450,000 additional shares available to underwriters.
Intersect Ent, maker of drug-eluting devices designed to treat ear, nose & throat conditions, raised $55 million in an initial public offering last July. The company raised a $30 million Series D round in February 2013 that included a contribution from Medtronic. An earlier round in November 2010 also raised $30 million.